Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high... see more

TSX:SZLS - Post Discussion

StageZero Life Sciences Ltd > Questions for this Presentation
View:
Post by johnny007 on Apr 22, 2021 8:55am

Questions for this Presentation

Not going into to deep into details, but I like the following to be addressed.

(
a1) Is there a shareholder vote on the merger with Health Clinic, widening Stage Zero's focus into treating cancer?

(a2) Will you disclose the financial details of this company?

(a3) What are their annual operating income or cash used?

(b1) How do you compare Aristotle specificity with competitors?
Is around 10% potential false positive acceptable in the market?
Comment by johnny007 on Apr 22, 2021 9:02am
and that's it, silent exit. Not addressing the financials, SH vote or Aristotle accuracy or acceptance (more trials etc). Bye. Sorry for the typos, early in the morning.
Comment by Nailbiter1 on Apr 22, 2021 9:06am
This post has been removed in accordance with Community Policy
Comment by johnny007 on Apr 22, 2021 9:16am
No, to pull in material investors he needs to address exactly these questions on financials. Normally you would file form S-4 in the US, disclosing all of that: Balance sheet, income and cash flow. This is not a tiny acquisition, but a merger giving roughly 38% to new company and widening the whole business spectrum. In the end, the 'new company' will be different. So this is quite ...more  
Comment by Mykndrsn on Apr 22, 2021 9:10am
Baseless concerns but 9:30 is soon. See ya!
Comment by gojotv! on Apr 22, 2021 1:19pm
All that stuff was addressed before, and you can register for one-on-one interaction through the "Micro-cap" site. Do your DD.
Comment by molotov420 on Apr 22, 2021 4:25pm
Thank god he didnt say 1+1=3 lol. Someone must have told him to cut that dumb shyt out.  One thing to note is he seemed to hint that Covid revs are unpredictable now...maybe we dont see such high amounts in one of the upcoming quarters. 
Comment by Jonnyboy85 on Apr 22, 2021 4:37pm
He was just talking over most of the ignorant stockhouse bullboard gutter trash heads:) no wonder none of you got it. There are no stupid ideas, only stupid people. https://hbr.org/2015/08/making-mergers-acquisitions-and-other-business-combinations-work In casual conversation, the idea of creating value in combinations is often expressed as 1 + 1 = 3, or some such mathematical metaphor.  ...more  
Comment by molotov420 on Apr 22, 2021 4:47pm
Jeez you so smart...I get the concept, without your google searches. Lighten up, it was a joke.
Comment by gojotv! on Apr 22, 2021 5:16pm
You're a patient man, Jonnyboy. Our bashers are armchair managers who don't know the first thing about business in genral, let alone this one. I wouldn't have had the patience. I woulda just said, "Read Dr. Covey" and left to find more money to buy shares.. I'm not above profiting from the ignorance of others... lol.
Comment by NewToInvesting7 on Apr 22, 2021 5:08pm
It makes sense that covid revenues will be unpredictable going forward.  I believe the majority of their covid testing revenues came from the US, and with so many people already vaccinated in the US, I don't think it's realistic to assume that there would continue to be a continuous upward trajectory for covid testing revenues. I hope one of the reasons for any reduction in covid ...more  
Comment by StockscoutX on Apr 22, 2021 7:12pm
Covid testing revenues are here to stay. It's been said that the covid vaccines will not stop you from being reinfected. Furthermore, as more variants show up, testing will be the only option to detect and isolate infected victims.
Comment by davewho on Apr 22, 2021 8:46pm
Pretty sure James said today that they expect covid testing to continue well into next year 2022. As of today the stats say only 26% of the US is fully vaccinated. With virus variants appearing at an alarming rate vaccination rates could prove to be meaningless. We may need to be tested and vaccinated yearly just like the flu. Especially for travellers.
Comment by Liked2Think on Apr 22, 2021 9:49pm
Tripp has said alot of things and most of the things he has said he would have all the information, they werent "guesses" like how long covid testing will go on for. Yet so many of the things never happened, werent true, or just failed like the rollout did. Face it Tripp screwed up massively.  No one cares about a 4 minute virtual presentation. I think its obvious Tripp is not the ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities